We advised Daiichi Sankyo on a global collaboration to develop and commercialize three of its DXd antibody-drug conjugate (ADC) candidates, patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd).

The collaboration, valued at US$22 billion, builds on Daiichi Sankyo’s commitment to develop novel medicines for patients with cancer.

Lawyers in our Northern Virginia office led the transaction, with support from our New York, Tokyo, and Washington, D.C. offices and our antitrust, intellectual property, regulatory, and tax practices.

We advised Merck, a global biopharmaceutical company known as MSD outside of the United States and Canada, on its acquisition of CN201, a novel autoimmune treatment drug.

Merck plans to evaluate CN201 as a treatment for B-cell malignancies and to investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.

Lawyers in our Washington, D.C. and Baltimore offices led the transaction, with support from our Beijing, Denver, Hong Kong, London, Los Angeles, New York, Northern Virginia, and Shanghai offices and our employee benefits, employment, intellectual property, international trade, privacy and cybersecurity, real estate, regulatory, and tax practices.

We advised Orlando Health, a U.S.-based not-for-profit health care system, on its acquisition of three hospitals and related physician practices from Steward Health Care, the largest physician-led, integrated health care system in the United States.

This transaction was part of Steward’s Chapter 11 bankruptcy proceeding, one of the largest and most complex hospital bankruptcy proceedings ever filed.

Lawyers from our health care, M&A, and restructuring teams in our Los Angeles, New York, Silicon Valley, and Washington, D.C. offices led the transaction, with support from several U.S. offices and our antitrust, employee benefits, employment, environment, intellectual property, litigation, privacy and cybersecurity, private equity, real estate, regulatory, and tax practices.

We advised Recordati, an international pharmaceutical company, on its acquisition of the global rights to Enjaymo® (sutimlimab) from Sanofi, a multinational pharmaceutical company, for a consideration of US$825 million plus additional commercial milestone payments of up to US$250 million.

The transaction aligns with Recordati’s broader strategy, reaffirms its commitment to the rare diseases space, and complements its oncology portfolio.

Lawyers in our Milan, Washington, D.C., and Baltimore offices led the transaction, with support from our Düsseldorf, Frankfurt, London, Los Angeles, New York, Rome, and Tokyo offices and our employee benefits, employment, intellectual property, regulatory, and tax practices.